Ideaya Biosciences
NASDAQ: IDYASouth San Francisco, US · Founded 2015 · Delaware corporation · 3 known investors
IDEAYA is a precision medicine oncology company developing first-in-class targeted therapies and rational drug combinations for molecularly defined, hard-to-treat cancers. Its lead candidate, darovasertib, is in late-stage trials for uveal melanoma, with a pipeline spanning PKC inhibition, ADC+DDR combinations, the MTAP pathway, and KAT6/7 inhibition.
Founders & leadership
Ideaya Biosciences was founded in 2015 by Yujiro Hata.
Board
Investors · 3
Reported raises · per SEC filings
Form D private placements$111.4M disclosed across 2 rounds · 2016–2018
▶$94MraisedMay 2018 · 23 investors · BiotechnologyRule 506(b)
- Paul A. StoneExecutive Officer
- Yujiro S. HataDirector, Executive Officer
- Jeffrey HagerExecutive Officer
- Edward HuDirector
- Jeffrey SteinDirector
- Terry RosenDirector
- John D. DiekmanDirector
- Brian DanielsDirector
- Timothy ShannonDirector
- Tim SmithExecutive Officer
- Thilo SchroederDirector
- Michael P. DillonExecutive Officer
- Offering amount
- $94M
- Amount sold
- $94M
- First sale
- Jan 2018
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$17.4MraisedAug 2016 · 10 investors · OtherRule 506(b)
- Paul StoneExecutive Officer
- Yujiro HataExecutive Officer, Director
- Timothy ShannonDirector
- Terry RosenDirector
- Jeffrey SteinDirector
- John DiekmanDirector
- Offering amount
- $46.2M
- Amount sold
- $17.4M
- First sale
- Mar 2016
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlapCompanies competing with Ideaya Biosciences for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Ideaya Biosciences do?
- IDEAYA is a precision medicine oncology company developing first-in-class targeted therapies and rational drug combinations for molecularly defined, hard-to-treat cancers. Its lead candidate, darovasertib, is in late-stage trials for uveal melanoma, with a pipeline spanning PKC inhibition, ADC+DDR combinations, the MTAP pathway, and KAT6/7 inhibition.
- Who founded Ideaya Biosciences?
- Ideaya Biosciences was founded by Yujiro Hata in 2015.
- Who are Ideaya Biosciences's investors?
- Ideaya Biosciences's investors include 5AM Ventures, Canaan Partners, Nextech Invest.
- How much funding has Ideaya Biosciences raised?
- Ideaya Biosciences has disclosed $111.4M raised across 2 rounds.
- Where is Ideaya Biosciences headquartered?
- Ideaya Biosciences is headquartered in South San Francisco, US.